

09-04-2001

FORM PTO-1595
1-31-92

REC'D



U.S. DEPARTMENT OF COMMERCE
Patent and Trademark

101832170

To the Honorable Commissioner of Patents and Trade.

ants or copy thereof.

1. Name of conveying party(ies): 8/24/01
Mark David Andrews
David Hepworth
Donald Stuart Middleton
Alan Stobie
Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies):
Name: Pfizer Inc.
Street Address: 235 East 42nd Street, 20th Floor
City: New York State: New York Zip: 10017-5755

10976 U.S. PTO
09/939475
08/24/01

3. Nature of conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other _____
Execution Date: June 29, 2001

Additional name(s) & address(es) attached? Yes No
09/939475

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: 08/24/01
A. Patent Application No.(s)
B. Patent No. (s)
Additional numbers attached? Yes No

PC10944AGLK

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Gregg C. Benson
Internal Address: Pfizer Inc.
Street Address: Eastern Point Road, MS 4159
City: Groton State: Connecticut ZIP: 06340

6. Total number of pages including cover sheet, attachments and document:
7. Total fee (37 CFR 3.41).....\$ 40.00
 Enclosed
 Authorized to be charged to deposit account
8. Deposit account number:
16-1445
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached document is the original or a true copy of the original document.
Gabriel L. Kleiman 8/24/01
Name of Person Signing Signature Date
Total number of pages including cover sheet:

OMB No. 0651-0011 (exp. 4/94)
Do not detach this portion
Mail documents to be recorded with required cover sheet information to:
**Box Assignments
Director - U.S. Patents and Trademark Office
Washington, D.C. 20231**
Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

CONFORMS WITH FORM PTO-1595
09/04/2001 AAHMED1 00000034 161445 09939475
1 FC:581 40.00 CH
EXPRESS MAIL NO. EL911724305US
ASSIGNMENT RECORDAL CVR SHEET (GROTON) TO COMMIS (FILED PREV).DOT, 9/99

PATENT
REEL: 012122 FRAME: 0581

Joint Inventors
Pfizer - US Only

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged we **Mark David ANDREWS, David HEPWORTH, Donald Stuart MIDDLETON and Alan STOBIE** c/o Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom, respectively, hereby sell, assign and transfer unto **PFIZER INC.**, a corporation organised and existing under the laws of the State of Delaware, and having a place of business at 235 East 42nd Street, New York, N.Y. 10017, United States of America, the entire right, title, and interest in and to our application for Letters Patent of the United States, executed the 29 day of June 2001 entitled **PHENOXYPHENYLHETEROCYCLE DERIVATIVES AS SSRIs** and our entire right, title and interest in the United States in and to all our inventions, whether joint or sole, disclosed in said application for Letters Patent, and in and to all United States patents granted on the foregoing inventions, and we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.


Signed and witnessed this 29 day of June 2001
at Sandwich, Kent, England.



Mark David ANDREWS




David HEPWORTH



Donald Stuart MIDDLETON

Alan STOBIE

In the presence of:



Teresa Griffiths

EXPRESS MAIL NO. EL911724305US

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged we **Mark David ANDREWS, David HEPWORTH, Donald Stuart MIDDLETON and Alan STOBIE** c/o Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom, respectively, hereby sell, assign and transfer unto **PFIZER INC.**, a corporation organised and existing under the laws of the State of Delaware, and having a place of business at 235 East 42nd Street, New York, N.Y. 10017, United States of America, the entire right, title, and interest in and to our application for Letters Patent of the United States, executed the 29 day of June 2001 entitled **PHENOXYPHENYLHETEROCYCLE DERIVATIVES AS SSRIs** and our entire right, title and interest in the United States in and to all our inventions, whether joint or sole, disclosed in said application for Letters Patent, and in and to all United States patents granted on the foregoing inventions, and we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Signed and witnessed this 29 day of June 2001
at Sandwich, Kent, England.


Mark David ANDREWS

David HEPWORTH

Donald Stuart MIDDLETON

Alan STOBIE

In the presence of:



Teresa GriffithsEXPRESS MAIL NO. EL91172430565